Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study
Authors:
Open Access
- 1 December 2019
- journal article
- research article
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 407, 116419
Abstract
No abstract availableKeywords
Funding Information
- Alexion Pharmaceuticals
This publication has 27 references indexed in Scilit:
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2013
- The Myasthenia Gravis‐Specific Activities of Daily Living ProfileAnnals of the New York Academy of Sciences, 2012
- Complement and cytokine based therapeutic strategies in myasthenia gravisJournal of Autoimmunity, 2011
- The MG CompositeNeurology, 2010
- Construct and concurrent validation of the MG‐QOL15 in the practice settingMuscle & Nerve, 2009
- Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuriaNature Biotechnology, 2007
- Myasthenia gravis: past, present, and futureJournal of Clinical Investigation, 2006
- Clinical and serological study of myasthenia gravis in HuBei Province, ChinaJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Reliability Testing of the Quantitative Myasthenia Gravis ScoreaAnnals of the New York Academy of Sciences, 1998
- Heterogeneity in myasthenia gravis: HLA phenotypes and autoantibody responses in ocular and generalized typesAnnals of Neurology, 1987